Novel Targeting of Cyclooxygenase-2 (COX-2) Pre-mRNA Using Antisense Morpholino Oligonucleotides Directed to the 3′ Acceptor and 5′ Donor Splice Sites of Exon 4: Suppression of COX-2 Activity in Human Amnion-Derived WISH and Myometrial Cells
Open Access
- 1 March 2006
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 69 (3) , 796-804
- https://doi.org/10.1124/mol.105.020529
Abstract
Increased expression of cyclooxygenase-2 (COX-2) has been implicated in the onset of both term and preterm labor. In this context, both selective and nonselective COX-2 inhibitors have been used in clinical trials to determine their efficacy in delaying preterm labor. However, recent evidence indicates that these tocolytics may have potentially adverse fetal and maternal side effects. Therefore, the development of more specific and nontoxic agents to inhibit COX-2 needs to be considered. We have evaluated whether antisense morpholino oligonucleotides have therapeutic potential in inhibiting COX-2 by specifically targeting both the 3′ and 5′ acceptor and donor sites of exon 4 of COX-2's pre-mRNA sequence. Confocal microscopy on “live” cells illustrated high levels of penetrance of antisense morpholino oligonucleotides using the Endo-Porter formula (Gene-Tools, LLC, Philomath, OR), with delivery efficiencies of 82 and 78%, respectively, in amnion-derived WISH and myometrial cells. Substantial inhibition by the morpholino oligonucleotides of COX-2 expression, induced by lipopolysaccharide administration, was observed at both the mRNA and protein levels. Loss of enzymic activity of COX-2 was confirmed using a sensitive COX enzyme activity assay, which reflects the rate of conversion of arachidonic acid to prostaglandin H2. Our results indicate that antisense morpholino oligonucleotides significantly inhibit expression and activity of this enzyme in in vitro cultures of amnion-WISH and myometrial cells. The potential thus exists that a similar approach can be mimicked in vivo to produce a highly specific and nontoxic strategy to inhibit COX-2 activity with its subsequent effects on the better management of preterm labor and other inflammatory conditions.This publication has 34 references indexed in Scilit:
- The Promise of Prostaglandins: Have They Fulfilled Their Potential as Therapeutic Targets for the Delay of Preterm Birth?Journal of the Society for Gynecologic Investigation, 2005
- TOCOX—A randomised, double‐blind, placebo‐controlled trial of rofecoxib (a COX‐2‐specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high riskBJOG: An International Journal of Obstetrics and Gynaecology, 2005
- A New Model for Inflammation-Induced Preterm Birth: The Role of Platelet-Activating Factor and Toll-Like Receptor-4The American Journal of Pathology, 2003
- A morpholino phenocopy of the colourless mutantGenesis, 2001
- Endocrine and Paracrine Regulation of Birth at Term and PretermEndocrine Reviews, 2000
- Spatio-Temporal Expression of the Trans-Acting Splicing Factors SF2/ASF and Heterogeneous Ribonuclear Proteins A1/A1B in the Myometrium of the Pregnant Human Uterus: A Molecular Mechanism for Regulating Regional Protein Isoform Expression in VivoJournal of Clinical Endocrinology & Metabolism, 2000
- The role of cyclooxygenases in inflammation, cancer, and developmentOncogene, 1999
- Multiple Female Reproductive Failures in Cyclooxygenase 2–Deficient MicePublished by Elsevier ,1997
- Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroidsJournal of Molecular Endocrinology, 1996
- Expression of cyclooxygenase types 1 and 2 in human fetal membranes at termAmerican Journal of Obstetrics and Gynecology, 1995